BRAFV600E
Oncogenic·Gain-of-function·Level 1·Level Dx2·FDA Level 22
BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers among others.
The BRAF V600E mutation is known to be oncogenic.
Genomic annotation powered by
Genome Nexus
genomenexus.orgHide mutation effect description
The class I activating exon 15 BRAF V600E mutation is located in the kinase domain of the BRAF protein and is highly recurrent in melanoma, lung and thyroid cancer, among others (PMID: 28783719, 26091043, 25079552, 23833300, 25417114, 28783719, 12068308). This mutation has been comprehensively biologically characterized and has been shown to activate the downstream MAPK pathway independent of RAS (PMID: 15035987, 12068308, 19251651, 26343582), to render BRAF constitutively activated in monomeric form (PMID: 20179705), and to retain sensitivity to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID: 26343582, 28783719, 20179705, 30351999).Select a cancer type
A list of the cancer type-specific BRAF alterations that may predict response to a targeted drug and the corresponding OncoKB™ level of evidence assigning their level of clinical actionability.
If you notice any mistakes or omissions, please reach out to us.
Level
Alterations
Level-associated cancer types
Drugs
Citations
Description
Diffuse Glioma (excluding Diffuse Intrinsic Pontine Glioma, Diffuse Astrocytoma, Anaplastic Oligodendroglioma, Oligodendroglioma, Oligoastrocytoma, Astrocytoma)
Vemurafenib + Cobimetinib
8
Loading...